Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

By D. Petrylak, C. Tangen, M. Hussain, P. Lara, Jeffrey A. Jones, M. Taplin, P. Burch, D. Berry, C. Moinpour, M. Kohli and 4 more. New England Journal of Medicine, 2004

3,752 citations recorded by the source corpus.

Subfields: Psychiatry and Mental health, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/93ad18158edb5941b9165b469a8c057bf9d7e060

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

Citations in the corpus

Prostate Cancer (2018, methodology): “The test was validated on biopsy specimens of 431 men with low- and intermediate-risk prostate cancer undergoing radical prostatectomy to determine the association with adverse pathology and recurrence of disease [9].”
Principal stratification analysis using principal scores (2016, background): “phase III trial (protocol 99-16) to compare the treatment of docetaxel and estramustine (DE) with mitoxantrone and prednisone (MP) in patients with metastatic, androgen-independent prostate cancer (Petrylak et al., 2004).”
Molecular genetics of prostate cancer: new prospects for old challenges. (2010, background): “Unfortunately, castration-resistant prostate cancer has been essentially untreatable, with the most effective standard chemotherapeutic regimens resulting in a mean increase in survival time of 2 mo (Petrylak et al. 2004; Tannock et al. 2004).”
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. (2007, background): “Docetaxel is now the standard of care across North America for patients with metastatic androgenindependent disease because of a survival advantage observed in two large randomized studies, and many other systemic therapies are currently being tested.(15,16) The hazard ratios reported by Tannock et ”
Identifiability and Estimation of Causal Effects by Principal Stratification With Outcomes Truncated by Death (2011, methodology): “Petrylak et al. (2004) have reported the overall survival benefit of taking DE over taking MP.”
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer (2009, background): “Interestingly, two recent clinical trials have shown that docetaxel, which disrupts mitosis by inhibiting the depolymerization of microtubules, can modestly improve survival of AIPC patients (Petrylak et al., 2004; Tannock et al., 2004), supporting an important role of M-phase in AIPC progression.”